Abstract
Abstract β2-glycoprotein I (β2-GPI) is a multifaceted protein with diverse biological functions, including triglyceride metabolism, blood coagulation and homeostasis. We previously reported that β2-GPI exhibits significant anti-migration effect on human aortic endothelial cells through the NF-κB/eNOS/NO signalling pathway. Migration of endothelial cells has known to be involved in vascular physiology and pathology, such as angiogenesis and tumorigenesis. We thus hypothesize that β2-GPI may also play a critical role in the regulation of tumor cell migration and invasion. Human plasma protein was precipitated by 3% (v/v) perchloric acid and β2-GPI was purified by heparin-Sepharose affinity chromatography. The purity of β2-GPI was determined by SDS/PAGE and Western blot analysis. The influence of β2-GPI on tumor cell migration was analyzed by wound healing and trans-well migration analysis. Using wound healing assay, we found that purified β2-GPI was able to inhibit cell migration in various tumor cancers, such as A375 human melanoma cancer cells, B16-F10 mouse melanoma cells, oral squamous cell carcinoma (OSCC)-derived cell line human tongue squamous carcinoma (SAS), and human head neck squamous cell carcinoma (HNSCC) cell lines FaDu (hypopharyngeal) carcinoma. In the trans-well assay, β2-GPI also showed markedly inhibition of tumor cell migration from the upper chamber to the lower chamber. Furthermore, β2-GPI revealed dose-dependently anti-invasion effect on melanoma cancer cells. The findings of the present study provide insight into the ability of β2-GPI to inhibit tumor cell migration, which indicates a novel direction for its application in anti-cancer therapy. Citation Format: An-Na Chiang, Wan-Chun Li, Shu-Hau Yeh, Shu-Wei Cheng, Yu-Shan Lin. The effect of beta2-glycoprotein I on anti-tumor cell migration. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A142.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
